Terran Biosciences

Executive Summary

Terran Biosciences is a private biotech platform company targeting neurological and psychiatric diseases through a combination of late-stage therapeutics, a proprietary psychedelic drug design engine, and an FDA-cleared AI neuroimaging software platform. Founded in 2019, the company’s lead programs include a Phase 3-ready schizophrenia therapy and selective serotonin 2A receptor antagonists, positioning it to address major unmet needs in mental health. The platform approach enables rapid iterative development across drug discovery, clinical trials, and digital diagnostics, potentially reducing costs and timelines while improving patient outcomes. The company’s most advanced asset targets schizophrenia, a large market with limited innovation, and is expected to generate pivotal data in the near term. Additionally, the FDA-cleared neuroimaging software provides a near-term revenue stream and strategic differentiation. Key upcoming catalysts include Phase 3 data readouts, potential regulatory submissions, and commercial scaling of the software platform. With a robust pipeline and platform technology, Terran is well-positioned for value creation, though execution risks remain typical of late-stage biotech.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 data readout for schizophrenia candidate65% success
• Q2 2026Expansion of FDA clearance for neuroimaging software to new indications80% success
• Q4 2026Initiation of Phase 2/3 trial for psychedelic-assisted therapy candidate50% success